ClinicalTrials.gg
RecruitingNCT03237026Updated Sep 21, 2026

Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients

An observational study in Prostate Cancer, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to male participants aged 30 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by National Taiwan University Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2017; still recruiting 9 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
360
Ages
30 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Prostatic Neoplasms by National Taiwan University Hospital — 7 open to participants now, 7 under way, none of them phase 3. Prostatic Neoplasms · National Taiwan University Hospital.

Started
2017
with 1 other
Observational
9 of 16
2 open now
Registered
8th of 16
by date

Among the 16 studies in Prostatic Neoplasms by National Taiwan University Hospital, this one is one of 2 that started in 2017, is one of 9 observational ones, and was the 8th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 16 studies in Prostatic Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 30 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Prostatic Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

The study aims to identify potential urine marker metabolites as predictive or prognostic markers for treatment outcomes in patients with prostate cancer.

Read the detailed description

This is a single-center single-arm translational study where patients with prostate cancer who are about to receive definitive treatments will be invited to participate the study. After signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study to identify potential metabolite and protein markers that are able to predict responses (including efficacy and side effects) to definitive treatments. All subjects who have received varied treatment before the study can NOT be recruited.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • prostatectomy
  • prostate radiotherapy
  • chemotherapy
  • immunotherapy
  • biomarkers
  • metabolomics
  • proteomics
  • urine
04

Who can participate

Ages eligible
30 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A. Expected subject number to be enrolled: 360 men at NTUH.

  1. Radical prostatectomy (OP, N=100): 50 subjects each for Cohort A and Cohort B, respectively.
  2. Radiotherapy (RT, N=140): 70 subjects each for Cohort A and Cohort B, respectively.
  3. Androgen-deprivation therapy (ADT, N=60): 30 subjects each for Cohort A and Cohort B, respectively
  4. Systemic chemotherapy (Chemo, N=60): 30 subjects for Cohort A and Cohort B, respectively

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have histopathologically confirmed prostate adenocarcinoma.
  2. Subjects who age 30 years to 100 years
  3. Subjects who agree to undergo the any of the following four treatments, including radical prostatectomy, definitive prostate radiotherapy, systemic chemotherapy, and androgen deprivation therapy for prostate cancer.
  4. Subjects who understand and will comply with the entire study procedures, consent to donate his spot urine (once for 50 ml) for urine metabolomics and proteomic profiling, and agree with subsequent collection and analysis of his clinical information including results of and the details of treatments and outcomes. (Note: Subjects will be told that the urine metabolomics and proteomics results will not be revealed to them.)

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have other cancers that have not been curatively treated or are disease-free for only 3 years or less. Subjects who have other genitourinary cancers (urothelial, renal cell, etc) are NOT allowed no matter what the disease-free duration is. However, subjects who have been curatively treated and are disease-free for 3 years or longer are allowed to be enrolled.
  2. Subjects who have severe organ function impairment which may significantly alter general cell metabolism or proteomics profiles determined by the investigators, such as Cre > 3.0, > 9.0%, symptomatic heart failure, or other symptomatic metabolic diseases.
  3. Subjects who have significant infection or inflammation within 8 weeks of the .
  4. Subjects who are taking medicine(s) that may, deemed by the investigators, substantially affect cell metabolism and proteomics profiles.
  5. Subjects who have a less than 12 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
360 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A

    Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.

    Other: No intervention required

  • Cohort B

    Validation cohort will be recruited in the next 24 months of the study period .

    Other: No intervention required

Interventions

  • OtherNo intervention required

    No intervention required

06

What researchers measure

Primary outcomes

  1. Biochemical recurrence or progression

    Time frame: 5 years

  2. toxicity profile, survival

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2017 (actual). Primary completion is estimated for Jan 2027, 111 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 111 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2017
First posted
Aug 2, 2017
StartActual
Oct 11, 2017
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jul 31, 2031
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03237026
Responsible party
Sponsor
First posted
Aug 2, 2017
Start date
Oct 11, 2017
Primary completion
Jan 15, 2027 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Sep 21, 2026

Study contacts

Chung-Hsin Chen, MD PhD
Contact
mufasachen@gmail.com
886-2-23123456 ext. 65242
Yeong-Shiau Pu, MD PhD
Contact
pu5249@ntuh.gov.tw
886-2-23123456 ext. 65254
Yeong-Shiau Pu, MD PhD
principal investigator · Department of Urology, National Taiwan University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion